NASDAQ:MEDPMedpace Stock Price, Forecast & News

Medpace's stock was trading at $83.64 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, MEDP shares have increased by 48.3% and is now trading at $124.06.
View which stocks have been most impacted by Coronavirus.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medpace in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Medpace.

Medpace is scheduled to release its next quarterly earnings announcement on Monday, October 26th 2020.
View our earnings forecast for Medpace.

Medpace Holdings Inc (NASDAQ:MEDP) released its quarterly earnings data on Monday, July, 27th. The company reported $0.68 earnings per share for the quarter, beating the consensus estimate of $0.40 by $0.28. The firm had revenue of $205 million for the quarter, compared to analyst estimates of $181.17 million. Medpace had a return on equity of 16.05% and a net margin of 12.11%. The firm's revenue for the quarter was down 4.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.81 EPS.
View Medpace's earnings history.

Medpace issued an update on its FY20 earnings guidance on Monday, July, 27th. The company provided EPS guidance of $3.62-3.83 for the period, compared to the Thomson Reuters consensus estimate of $2.33. The company issued revenue guidance of $880-920 million, compared to the consensus revenue estimate of $831.87 million.

5 Wall Street analysts have issued 12-month target prices for Medpace's stock. Their forecasts range from $75.00 to $124.00. On average, they expect Medpace's stock price to reach $97.67 in the next year. This suggests that the stock has a possible downside of 21.3%.
View analysts' price targets for Medpace.

News coverage about MEDP stock has trended neutral recently, according to InfoTrie Sentiment. The research firm identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Medpace earned a news impact score of 0.2 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near future.
View the latest news about Medpace.

Some companies that are related to Medpace include EXACT Sciences (EXAS), PPD (PPD), Charles River Laboratories Intl. (CRL), Icon (ICLR), Exelixis (EXEL), Syneos Health (SYNH), PRA Health Sciences (PRAH), BTG (BTGGF), National Research (NRC), Precigen (PGEN), STARPHARMA HOLD/S (SPHRY), Anavex Life Sciences (AVXL), Luna Innovations (LUNA), Pieris Pharmaceuticals (PIRS) and Eloxx Pharmaceuticals (ELOX).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Medpace investors own include NVIDIA (NVDA), EXACT Sciences (EXAS), Baidu (BIDU), Advanced Micro Devices (AMD), Alibaba Group (BABA), Square (SQ), JD.Com (JD), Cisco Systems (CSCO), Intuitive Surgical (ISRG) and Trade Desk (TTD).

(MEDP) raised $150 million in an initial public offering on Thursday, August 11th 2016. The company issued 7,000,000 shares at $20.00-$23.00 per share. Jefferies, Credit Suisse, UBS Investment Bank and Wells Fargo Securities served as the underwriters for the IPO and Baird and William Blair were co-managers.

Medpace trades on the NASDAQ under the ticker symbol "MEDP."

Medpace's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Pendal Group Ltd (3.04%), Boston Trust Walden Corp (1.11%), Fisher Asset Management LLC (1.01%), Principal Financial Group Inc. (0.63%), Redwood Investments LLC (0.62%) and Tributary Capital Management LLC (0.55%). Company insiders that own Medpace stock include August J Troendle, Jesse J Geiger, Medpace Investors, Llc, Medpace Limited Partnership, Stephen P Ewald and Susan E Burwig.
View institutional ownership trends for Medpace.

MEDP stock was sold by a variety of institutional investors in the last quarter, including MERIAN GLOBAL INVESTORS UK Ltd, WINTON GROUP Ltd, Russell Investments Group Ltd., Mackay Shields LLC, Fisher Asset Management LLC, Pendal Group Ltd, First Trust Advisors LP, and Principal Financial Group Inc.. Company insiders that have sold Medpace company stock in the last year include August J Troendle, Jesse J Geiger, Medpace Investors, Llc, Stephen P Ewald, and Susan E Burwig.
View insider buying and selling activity for Medpace.

MEDP stock was purchased by a variety of institutional investors in the last quarter, including Boston Trust Walden Corp, Redwood Investments LLC, Raymond James & Associates, Tributary Capital Management LLC, SG Americas Securities LLC, Congress Asset Management Co. MA, Swiss National Bank, and Great Lakes Advisors LLC.
View insider buying and selling activity for Medpace.

Shares of MEDP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of MEDP stock can currently be purchased for approximately $124.06.

Medpace has a market capitalization of $4.39 billion and generates $860.97 million in revenue each year. The company earns $100.44 million in net income (profit) each year or $3.02 on an earnings per share basis. Medpace employs 3,500 workers across the globe.

The official website for Medpace is www.medpace.com.

Medpace's mailing address is 5375 MEDPACE WAY, CINCINNATI OH, 45227. The company can be reached via phone at 513-579-9911 or via email at [email protected]